Matthew Brouillette, MPH

Treatment Discontinuation of Long-Acting Injectables or Oral Atypical Antipsychotics Among Medicaid Recipients With Schizophrenia

OBJECTIVE: Compare treatment discontinuation of atypical long-acting injectables (LAIs) and oral atypical antipsychotics (OAA) in patients with schizophrenia.

Xue Song , PhD;

Antoine C. El Khoury , PhD;

Matthew Brouillette , MPH;

Kruti Joshi , MPH, MD;

David Smith , PhD, MD, MBBS, DPM;

03/01/2019

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Matthew Brouillette, MPH

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products